When Should You Stop Wegovy for Weight Loss?

The 5% rule: where it comes from and what it means in practice

NICE's technology appraisal of semaglutide (TA875) states that treatment should be reviewed if less than 5% of body weight has been lost after six months on the maintenance dose. This is not an arbitrary number. The STEP programme's data showed a clear separation between participants who responded to semaglutide and those who did not, and modest early response was a strong predictor of eventual outcome. Six months gives the medicine a genuine trial period, it takes time to tolerate dose titration, and the maintenance dose is only reached after roughly four months of gradual increases. Stopping earlier than that, simply because the scales haven't shifted much in the first few weeks, would be premature. But if the maintenance dose has been reached and held for several months without meaningful progress, the benefit-risk calculation changes. Your prescriber will look at the full picture: how much weight has been lost, what side effects you have experienced, and whether your original health goals have been met. If you want to understand when to stop Wegovy and what the key decision points look like, the threshold is best understood as a prompt for that conversation, not an automatic off switch.

If you're wondering how quickly results typically arrive, our page on when Wegovy weight loss starts sets out what the trial data show in the early weeks.

The two-year ceiling on NHS treatment

For patients accessing semaglutide through the NHS, NICE TA875 sets a maximum treatment duration of two years within a specialist weight management service. This limit applies specifically to NHS commissioning and reflects both cost-effectiveness modelling and the practical reality that weight-loss medicines have been evaluated over trial periods of 68 to 72 weeks, not indefinitely. The two-year point is therefore a natural review, not necessarily a hard stop for everyone. A prescriber will assess whether the health gains achieved are sustained, whether ongoing treatment remains clinically appropriate, and whether alternative strategies are better suited at that stage. Private patients are not subject to the same two-year rule in law, but a responsible prescriber (including those at our pharmacy) will review benefit and risk continuously, exactly as they would for any long-term medicine. No repeat prescription is issued without a clinical re-review at nume.

Medical reasons to stop earlier than planned

Some circumstances require stopping Wegovy sooner than the six-month review point. Pregnancy is the clearest: semaglutide is not recommended during pregnancy, breastfeeding, or when actively trying to conceive. Women of childbearing age planning a pregnancy should discuss timing with their prescriber well in advance. Severe or persistent gastrointestinal side effects (particularly signs of pancreatitis (severe stomach pain reaching through to the back, with or without vomiting)) require urgent medical attention and may mean stopping treatment. The MHRA has issued Drug Safety Updates for GLP-1 medicines covering these situations, and any suspected side effect can be reported at yellowcard.mhra.gov.uk. Gallbladder problems, signs of a serious allergic reaction, or other conditions that emerge during treatment may also prompt a prescriber to pause or stop the medicine. The right response is always to contact your clinical team rather than making that decision alone. You can reach our team through our support page, available seven days a week.

What happens to your weight after stopping, and how to approach that

This is the part most people want to know about, and the data are honest on the point: weight regain is common. A study in the withdrawal phase of the STEP 1 programme found that participants regained most of the lost weight within a year of stopping semaglutide when no additional support was in place. That doesn't mean treatment was futile, understanding how Wegovy weight loss works and what drives the results helps explain why metabolic and cardiovascular risk markers improved during the treatment period, and for many people the window of reduced appetite is the time to build habits that may outlast the medicine. It does mean that stopping Wegovy shouldn't be a sudden decision made because of cost, a holiday, or a missed delivery. If you have concerns about what happens to your weight after stopping Wegovy, that's a conversation worth having with your prescriber before stopping, not after. Similarly, if your progress has stalled but you haven't yet hit the six-month review point, the question of what to do when weight loss plateaus is a separate one with its own answers. If you'd like a broader overview of how the active ingredient works, our guide to semaglutide covers the mechanism and the evidence behind it. Planning your stopping point around your routine makes sense, pausing because a pen runs out over a bank holiday weekend, without clinical input, doesn't. Keep your prescriber in the loop before any gap in treatment.